[Evaluation of vaccine potency against viral hepatitis B performed with HB-vax II vaccine in a group with an increased risk for hepatitis B].
The aim of this investigation was to established the rate of seroconversion against hepatitis B after vaccination of workers of the National Institute of Cardiology who are at increased risk. All participants were HBs-Ag, and anti-HBs negative and also had normal standard hepatic laboratory tests. Vaccination was carried out according to following scheme: the first vaccination at t = 0, the second after one month and the third after six months. Vaccine was given intramuscular. The success of vaccination was monitored by the quantitative determination of antibodies against HBs-Ag (Anti-HBs) by the ELISA method (Abbott). After each vaccination, anti-HBs formation above 10 iu/l protective level was observed in 40.7%, 85.9%, and 97.1% of immunocompetent subjects after first, second, and third vaccination respectively. The acquired anti-HBs titer varies from individual to individual but in immunocompetent subjects the level of antibodies against HBs after third vaccination was 170 fold higher then those after first vaccination. These results seems to suggest that vaccine HB-Vax-II is effective and may by recommended in pre-exposure prophylaxis against hepatitis B.
Leśnik
J
J
Przychodni Poliklinicznej Instytutu Kardiologii w Warszawie.
Cieślak
A
A
Krychniak
E
E
Sitkiewicz
D
D
D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009316:National Institutes of Health (U.S.); D009784:Occupational Diseases / Q000517:prevention & control*; D018570:Risk Assessment; D012698:Serologic Tests; D014481:United States
C075659:HB-VAX; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines
Ocena skuteczności szczepień przeciwko wzw typu B przeprowadzonych szczepionka HB-vax II w grupie zwiekszonego ryzyka na zakazenie wirusem B.